Pharmacological evaluation of novel bioisosteres of an adamantanyl benzamide P2X7 receptor antagonist

Wilkinson, Shane M, Barron, Melissa L, O'Brien-Brown, James, Janssen, Bieneke, Stokes, Leanne ORCID: https://orcid.org/0000-0003-4013-6781, Werry, Eryn L., Chishty, Mansoor, Skarratt, Kristen K., Ong, Jennifer A., Hibbs, David E., Vugts, Danielle J., Fuller, Stephen, Windhorst, Albert D. and Kassiou, Michael (2017) Pharmacological evaluation of novel bioisosteres of an adamantanyl benzamide P2X7 receptor antagonist. ACS Chemical Neuroscience, 8 (11). 2374–2380. ISSN 1948-7193

[thumbnail of Accepted manuscript]
Preview
PDF (Accepted manuscript) - Accepted Version
Download (559kB) | Preview

Abstract

Adamantanyl benzamide 1 was identified as a potent P2X7R antagonist but failed to progress further due to poor metabolic stability. We describe the synthesis and SAR of a series of bioisosteres of benzamide 1 to explore improvements in the pharmacological properties of this lead. Initial efforts investigated a series of heteroaromatic bioisosteres, which demonstrated improved physicochemical properties but reduced P2X7R antagonism. Installation of bioisosteric fluorine on the adamantane bridgeheads was well tolerated and led to a series of bioisosteres with improved physicochemical properties and metabolic stability. Trifluorinated benzamide 34 demonstrated optimal physicochemical parameters, superior metabolic stability (ten times longer than lead benzamide 1), and an improved physicokinetic profile and proved effective in the presence of several known P2X7R polymorphisms.

Item Type: Article
Faculty \ School: Faculty of Science > School of Pharmacy
UEA Research Groups: Faculty of Science > Research Groups > Molecular and Tissue Pharmacology
Depositing User: Pure Connector
Date Deposited: 23 Nov 2017 06:05
Last Modified: 22 Oct 2022 03:16
URI: https://ueaeprints.uea.ac.uk/id/eprint/65543
DOI: 10.1021/acschemneuro.7b00272

Downloads

Downloads per month over past year

Actions (login required)

View Item View Item